YC Investment
AboutThesisApproachContactInquire
02 — Investment Thesis

Where Science Meets
Structural Mispricing

Small-cap biotech is a market of extremes. The best science often sits in companies whose valuations do not reflect their clinical potential — not because the science is weak, but because the capital markets strategy is broken. We invest at the intersection of scientific excellence and valuation dislocation.

01

Thematic Focus

We invest exclusively in U.S. and EU publicly listed small-cap biotech firms. This narrow mandate enables deep sector expertise and faster conviction on scientific merit.

02

Clinical Stage Entry

We enter early in the clinical development cycle — when risk is highest and valuation is lowest. Our scientific diligence allows us to underwrite risk that generalist investors cannot.

03

Valuation Dislocation

We specifically target companies undervalued due to mismanaged capital markets strategy. We bring both capital and the expertise to unlock that value.

04

PIPE Execution

We invest US$5–30 million primarily through newly issued public shares (PIPE). This structure aligns our interests directly with the company's growth trajectory.

Our Conviction
"The most valuable molecules in medicine are often hidden in plain sight — listed on public markets, undervalued, and waiting for the right partner to bring them to patients."